Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in gambian infants

Science Translational Medicine

Volumn 3, Issue 88, 2011, Pages

  Ota, Martin O C ^a   Odutola, Aderonke A ^a   Owiafe, Patrick K ^a   Donkor, Simon ^a   Owolabi, Olumuyiwa A ^a   Brittain, Nathaniel J ^b   Williams, Nicola ^c   Rowland Jones, Sarah ^a   Hill, Adrian V S ^b   Adegbola, Richard A ^d   McShane, Helen ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MODIFIED VACCINIA VIRUS ANKARA 85A VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BCG VACCINATION; BLOOD SAMPLING; BRONCHOPNEUMONIA; CELLULAR IMMUNITY; CONTROLLED STUDY; DIPHTHERIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC GROUP; GAMBIAN; HEALTH PROGRAM; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA; INJECTION SITE DESQUAMATION; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA; MEDICAL INFORMATION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUBERCULOSIS; URINARY TRACT INFECTION; ANTIBODY PRODUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GAMBIA; IMMUNOLOGY; PREVENTIVE HEALTH SERVICE; TIME; VACCINATION;

ANTIBODY FORMATION; BCG VACCINE; GAMBIA; HUMANS; IMMUNIZATION PROGRAMS; INFANT; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 79959486818     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002461     Document Type: Article

References (22)

1. C. Dye, C. J. Watt, D. M. Bleed, S. M. Hosseini, M. C. Raviglione, Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293, 2767-2775 (2005).
2. G. A. Colditz, T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, F. Mosteller, Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698-702 (1994).
3. M. L. Garly, C. L. Martins, C. Balé, M. A. Baldé, K. L. Hedegaard, P. Gustafson, I. M. Lisse, H. C. Whittle, P. Aaby, BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 21, 2782-2790 (2003).
4. M. O. Ota, J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P. H. Lambert, K. P. McAdam, C. A. Siegrist, A. Marchant, Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919-925 (2002).
5. S. P. Zodpey, S. N. Shrikhande, S. W. Kulkarni, B. R. Maldhure, Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: A case-control study. Indian J. Public Health 51, 184-189 (2007).
6. T. Hawkridge, T. J. Scriba, S. Gelderbloem, E. Smit, M. Tameris, S. Moyo, T. Lang, A. Veldsman, M. Hatherill, L. Merwe, H. A. Fletcher, H. Mahomed, A. V. Hill, W. A. Hanekom, G. D. Hussey, H. McShane, Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544-552 (2008).
7. H. McShane, A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, A. V. Hill, Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240-1244 (2004).
8. S. D'Souza, V. Rosseels, M. Romano, A. Tanghe, O. Denis, F. Jurion, N. Castiglione, A. Vanonckelen, K. Palfliet, K. Huygen, Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71, 483-493 (2003).
9. H. M. Vordermeier, B. Villarreal-Ramos, P. J. Cockle, M. McAulay, S. G. Rhodes, T. Thacker, S. C. Gilbert, H. McShane, A. V. Hill, Z. Xing, R. G. Hewinson, Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77, 3364-3373 (2009).
10. R. H. Brookes, P. C. Hill, P. K. Owiafe, H. B. Ibanga, D. J. Jeffries, S. A. Donkor, H. A. Fletcher, A. S. Hammond, C. Lienhardt, R. A. Adegbola, H. McShane, A. V. Hill, Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 3, e2921 (2008).
11. T. J. Scriba, M. Tameris, N. Mansoor, E. Smit, L. van der Merwe, F. Isaacs, A. Keyser, S. Moyo, N. Brittain, A. Lawrie, S. Gelderbloem, A. Veldsman, M. Hatherill, A. Hawkridge, A. V. Hill, G. D. Hussey, H. Mahomed, H. McShane, W. A. Hanekom, Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur. J. Immunol. 40, 279-290 (2010).
12. S. Abdulla, R. Oberholzer, O. Juma, S. Kubhoja, F. Machera, C. Membi, S. Omari, A. Urassa, H. Mshinda, A. Jumanne, N. Salim, M. Shomari, T. Aebi, D. M. Schellenberg, T. Carter, T. Villafana, M. A. Demoitié, M. C. Dubois, A. Leach, M. Lievens, J. Vekemans, J. Cohen, W. R. Ballou, M. Tanner, Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 359, 2533-2544 (2008).
13. M. Walther, F. M. Thompson, S. Dunachie, S. Keating, S. Todryk, T. Berthoud, L. Andrews, R. F. Andersen, A. Moore, S. C. Gilbert, I. Poulton, F. Dubovsky, E. Tierney, S. Correa, A. Huntcooke, G. Butcher, J. Williams, R. E. Sinden, A. V. Hill, Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect. Immun. 74, 2706-2716 (2006).
14. V. S. Moorthy, E. B. Imoukhuede, S. Keating, M. Pinder, D. Webster, M. A. Skinner, S. C. Gilbert, G. Walraven, A. V. Hill, Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189, 2213-2219 (2004).
15. B. Watson, A. Cawein, B. L. McKee, J. G. Hackell, Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants. Pediatr. Infect. Dis. J. 11, 930-935 (1992).
16. F. Zepp, A. Schuind, C. Meyer, R. Sänger, A. Kaufhold, P. Willems, Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 109, e58 (2002).
17. L. Bungener, F. Geeraedts, W. Ter Veer, J. Medema, J. Wilschut, A. Huckriede, Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26, 2350-2359 (2008).
18. D. Spazierer, H. Skvara, M. Dawid, N. Fallahi, K. Gruber, K. Rose, P. Lloyd, S. Heuerding, G. Stingl, T. Jung, T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. Clin. Exp. Allergy 39, 999-1008 (2009).
19. A. K. Abbas, K. M. Murphy, A. Sher, Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
20. J. L. Flynn, J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, B. R. Bloom, An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254 (1993).
21. M. J. Newport, C. M. Huxley, S. Huston, C. M. Hawrylowicz, B. A. Oostra, R. Williamson, M. Levin, A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941-1949 (1996).
22. Acknowledgments: We thank the Gambian government, the EPI program of Gambia, and staff of Sukuta Health Centre for their collaboration. We thank K. Flanagan, J. Adetifa, and the Sukuta field team for assisting us in this trial. We appreciate M. Sonko, K. Manneh, and S. Sanneh for their field work and A. Bojang and J. Sutherland for laboratory assistance. We also thank K. Bojang for safety monitoring; V. Thomas and J. Mueller for internal monitoring and support; A. Lawrie for coordination; S. Vermaak for help with data analysis; and C. McKenna for study monitoring. We are grateful to the parents and guardians who allowed their infants to participate in this trial. Funding: The study was funded by the Medical Research Council (UK) and the European Commission (EU 6th Framework; TBVAC). Neither funder had any role in the design of the study or the preparation of the manuscript. H.M. is a Wellcome Trust Senior Clinical Research Fellow, and A.V.S.H. is a Wellcome Trust Principal Research Fellow. Author contributions: M.O.C.O., H.M., A.V.S.H., S.R.-J., and R.A.A. designed the study. A.A.O., O.A.O., M.O.C.O., R.A.A., and S.R.-J. provided clinical help. M.O.C.O., A.A.O., N.J.B., and H.M. managed the project. P.K.O., M.O.C.O., H.M., A.V.S.H., and R.A.A. performed laboratory assays and analysis. N.W., S.D., N.J.B., H.M., and M.O.C.O. performed the statistical analysis. M.O.C.O., H.M., N.J.B., A.A.O., O.A.O., A.V.S.H., S.D., N.W., S.R.-J., and R.A.A. wrote the manuscript. Competing interests: A.V.S.H. and H.M. are named inventors on a patent filing related to MVA85A (International patent number WO 2006/072787 A1: Compositions for immunising against mycobacteria), and are shareholders in a joint venture, Oxford-Emergent Tuberculosis Consortium, formed for the future development of this vaccine. The other authors declare that they have no competing interests.